These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 6594926)
1. A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study. Bennett JM; Lymann GH; Cassileth PA; Glick JH; Oken MM Am J Clin Oncol; 1984 Oct; 7(5):471-3. PubMed ID: 6594926 [TBL] [Abstract][Full Text] [Related]
2. High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia. Van Echo DA; Wiernik PH; Aisner J Cancer Clin Trials; 1980; 3(4):325-8. PubMed ID: 6933027 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report. Chard RL; Krivit W; Bleyer WA; Hammond D Cancer Treat Rep; 1979; 63(11-12):1755-9. PubMed ID: 294306 [TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia. Paciucci PA; Davis RB; Holland JF; Martelo O; Schiffer CA Am J Clin Oncol; 1990 Dec; 13(6):516-9. PubMed ID: 2239806 [TBL] [Abstract][Full Text] [Related]
5. [Long-term oral administration of etoposide (VP-16) for the patients with refractory or relapsed acute non-lymphocytic leukemia]. Koyama S; Saitou H; Kashiwaba M Rinsho Ketsueki; 1991 Jul; 32(7):736-42. PubMed ID: 1920837 [TBL] [Abstract][Full Text] [Related]
6. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study. Slayton RE; Creasman WT; Petty W; Bundy B; Blessing JA Cancer Treat Rep; 1979; 63(11-12):2089-92. PubMed ID: 526942 [No Abstract] [Full Text] [Related]
7. High-dose carboplatin in the treatment of hematologic malignancies. Vogler WR Oncology; 1993 Nov; 50 Suppl 2():42-6. PubMed ID: 8233301 [TBL] [Abstract][Full Text] [Related]
8. Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer. Crivellari D; Veronesi A; Magri MD; Tirelli U; Comoretto R; Barzan L; Caruso G; Carbone A; Grigoletto E Tumori; 1985 Oct; 71(5):499-500. PubMed ID: 4060251 [TBL] [Abstract][Full Text] [Related]
10. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia. Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323 [TBL] [Abstract][Full Text] [Related]
11. Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B. Nissen NI; Pajak TF; Leone LA; Bloomfield CD; Kennedy BJ; Ellison RR; Silver RT; Weiss RB; Cuttner J; Falkson G; Kung F; Bergevin PR; Holland JF Cancer; 1980 Jan; 45(2):232-5. PubMed ID: 6985831 [TBL] [Abstract][Full Text] [Related]
12. Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213. Schiffer CA; DeBellis R; Kasdorf H; Wiernik PH Cancer Treat Rep; 1982 Feb; 66(2):267-71. PubMed ID: 6173123 [TBL] [Abstract][Full Text] [Related]
13. [Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies]. Kimura K; Yamada K; Yoshida T Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):496-501. PubMed ID: 3954373 [TBL] [Abstract][Full Text] [Related]
14. [A phase II trial of etoposide (VP-16) administered intravenously in the treatment of malignant lymphoma and acute leukemia]. Moriyama Y; Shibata A; Maekawa I; Yoshida Y; Miura A; Wakui A; Kariyone S; Maekawa T; Miura Y; Abe T Rinsho Ketsueki; 1985 Nov; 26(11):1774-84. PubMed ID: 3835288 [No Abstract] [Full Text] [Related]
15. [The treatment of acute myelocytic leukemia during the first recurrence by means of a new cytostatic combination]. Cavalli F; Sauter C; Senn HJ; Alberto P Schweiz Med Wochenschr; 1976 Sep; 106(38):1265-8. PubMed ID: 1070154 [TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA; J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813 [TBL] [Abstract][Full Text] [Related]
17. Continuous infusion diaziquone and etoposide: a phase I study in adult patients with acute leukemia. Lee EJ; Reck K; Schiffer CA Leukemia; 1990 Mar; 4(3):189-92. PubMed ID: 2314118 [TBL] [Abstract][Full Text] [Related]
18. Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995. Gordon MS; Young ML; Tallman MS; Cripe LD; Bennett JM; Paietta E; Longo W; Gerad H; Mazza J; Rowe JM Leuk Res; 2000 Oct; 24(10):871-5. PubMed ID: 10996206 [TBL] [Abstract][Full Text] [Related]
19. Phase II trial of VP-16-213 in advanced ovarian carcinoma. Hillcoat BL; Campbell JJ; Pepperell R; Quinn MA; Bishop JF; Day A Gynecol Oncol; 1985 Oct; 22(2):162-6. PubMed ID: 4054715 [TBL] [Abstract][Full Text] [Related]
20. Amsacrine and etoposide induced paralytic ileus in a patient with acute myelomonocytic leukemia. Kucuk O; Apostol JV J Surg Oncol; 1985 Mar; 28(3):172-3. PubMed ID: 3856083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]